Sirukumab
Sirukumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6.
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.
Clinical trials
Rheumatoid arthritis
It has started clinical trials. and reported some phase II results.In December 2015 three phase III trials were collecting data.
By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.